• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Navigating Challenges and Investor Rewards: Nu Skin Enterprises Ensures Steady Distribution amidst Changing Profits

    3/6/24 10:05:16 AM ET
    $MED
    $NUS
    Packaged Foods
    Consumer Staples
    Other Pharmaceuticals
    Health Care
    Get the next $MED alert in real time by email

    On March 06, 2024, Nu Skin Enterprises (NYSE:NUS) will distribute a dividend payout of $0.06 per share, equating to an annualized dividend yield of 1.38%. Shareholders who owned the stock before the ex-dividend date on February 23, 2024 will receive this payout.

    Nu Skin Enterprises Recent Dividend Payouts

    Ex-Date Payments per year Dividend Yield Announced Record Payable
    2024-02-23 4 $0.06 1.38% 2024-02-14 2024-02-26 2024-03-06
    2023-11-22 4 $0.39 8.21% 2023-11-01 2023-11-24 2023-12-06
    2023-08-24 4 $0.39 5.31% 2023-08-01 2023-08-25 2023-09-06
    2023-05-25 4 $0.39 3.91% 2023-05-03 2023-05-26 2023-06-07
    2023-02-24 4 $0.39 3.6% 2023-02-15 2023-02-27 2023-03-08
    2022-11-23 4 $0.39 3.93% 2022-11-02 2022-11-25 2022-12-07
    2022-08-25 4 $0.39 3.43% 2022-08-04 2022-08-26 2022-09-07
    2022-05-26 4 $0.39 3.45% 2022-05-04 2022-05-27 2022-06-08
    2022-02-25 4 $0.39 3.1% 2022-02-16 2022-02-28 2022-03-09
    2021-11-24 4 $0.38 3.78% 2021-11-03 2021-11-26 2021-12-08
    2021-08-26 4 $0.38 2.8% 2021-08-04 2021-08-27 2021-09-08
    2021-05-27 4 $0.38 2.92% 2021-05-05 2021-05-28 2021-06-09

    Nu Skin Enterprises lags behind its industry peers in terms of dividend yield, with Medifast (NYSE:MED) surpassing it with a higher annualized dividend yield of 17.00%.

    Analyzing Nu Skin Enterprises Financial Health

    Companies that pay out steady cash dividends are attractive to income-seeking investors, and companies that are financially healthy tend to maintain their dividend payout schedule. For this reason, investors can find it insightful to see if a company has been increasing or decreasing their dividend payout schedule and if their earnings are growing.

    YoY Growth in Dividend Per Share

    dividend chart graph

    Investors witnessed an upward trajectory in the company's dividend per share between 2020 and 2023. The dividend per share rose from $1.50 to $1.56, indicating the company's dedication to enhancing shareholder value through increased dividends.

    YoY Earnings Growth For Nu Skin Enterprises

    earning chart graph

    From 2020 to 2023, Nu Skin Enterprises experienced a decrease in earnings per share, dropping from $2.97 to $2.36. This declining earnings trend may be worrisome for income-seeking investors, as it indicates a potential impact on the company's ability to sustain or increase its cash dividend payouts. Further analysis is necessary to understand the underlying reasons for this decrease.

    Recap

    In this article, we explore the recent dividend payout of Nu Skin Enterprises and its significance for shareholders. The company has decided to distribute a dividend of $0.06 per share today, which equates to an annualized dividend yield of 1.38%.

    Nu Skin Enterprises lags behind its industry peers in terms of dividend yield, with Medifast surpassing it with a higher annualized dividend yield of 17.00%.

    With dividend per share increasing and earnings per share decreasing from 2020 to 2023, Nu Skin Enterprises seems to be emphasizing the distribution of profits to investors despite the decline in profitability.

    To stay informed about changes in financials or dividend disbursements, investors should pay close attention to the company's performance in the upcoming quarters.

    [See current stock movements Nu Skin Enterprises on Benzinga.](https://www.benzinga.com/quote/Nu Skin Enterprises (NYSE: NUS))

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $MED alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MED
    $NUS

    CompanyDatePrice TargetRatingAnalyst
    MEDIFAST INC
    $MED
    11/5/2024$16.50 → $17.00Underperform → Neutral
    DA Davidson
    MEDIFAST INC
    $MED
    6/5/2024$25.00 → $17.50Neutral → Underperform
    DA Davidson
    MEDIFAST INC
    $MED
    10/13/2023$82.00Equal-Weight
    Stephens
    Nu Skin Enterprises Inc.
    $NUS
    1/31/2023$43.00 → $39.00Buy → Hold
    Jefferies
    MEDIFAST INC
    $MED
    11/4/2022$278.00 → $106.00Buy → Neutral
    DA Davidson
    MEDIFAST INC
    $MED
    8/4/2022$345.00 → $150.00Buy → Hold
    Jefferies
    MEDIFAST INC
    $MED
    2/24/2022$349.00 → $341.00Buy
    DA Davidson
    Nu Skin Enterprises Inc.
    $NUS
    2/17/2022$47.00 → $50.00Neutral
    DA Davidson
    More analyst ratings

    $MED
    $NUS
    SEC Filings

    View All

    Nu Skin Enterprises Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

    3/20/26 4:16:06 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    MEDIFAST INC filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - MEDIFAST INC (0000910329) (Filer)

    3/20/26 8:35:54 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    Nu Skin Enterprises Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

    3/9/26 4:16:23 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $MED
    $NUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Woodbury Edwina D was granted 14 shares, increasing direct ownership by 0.03% to 42,993 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    3/12/26 5:03:45 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    EVP, President of Global Sales Keisel Justin S was granted 47,059 shares, increasing direct ownership by 42% to 160,170 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    3/9/26 6:14:06 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Chief Product Officer Hatchett Steven Keith was granted 77,941 shares, increasing direct ownership by 43% to 260,818 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    3/9/26 6:12:42 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $MED
    $NUS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nu Skin Enterprises Appoints Chelsea Lantz as Interim Chief Financial Officer

    Nu Skin Enterprises, Inc. (NYSE:NUS) today announced the appointment of Chelsea Lantz as interim Chief Financial Officer, effective immediately. The appointment of Lantz comes after James Thomas stepped down as CFO to pursue an outside opportunity. "On behalf of our board, management and the entire Nu Skin team, we thank James for his leadership and significant contributions over 16 years at Nu Skin and wish him and his family well in their future pursuits," said Ryan Napierski, president and CEO. "We have a talented finance team who has led the ongoing work to improve our operational performance and strengthen our balance sheet over the past year. I am excited to work directly with Chels

    3/20/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Medifast Announces Cooperation Agreement with Steamboat Capital

    Company Agrees to Nominate Parsa Kiai and Jeff Rose as Director Candidates at 2026 Annual Meeting of Stockholders Medifast, Inc. (NYSE:MED), the metabolic health and wellness company known for its science-backed, coach-guided lifestyle system, today announced the company's Board of Directors has agreed to nominate Parsa Kiai and Jeff Rose from Steamboat Capital Partners LLC as independent director candidates to stand for election at the company's 2026 Annual Meeting of Stockholders, which is provisionally scheduled for May 19, 2026. These nominations are pursuant to a Cooperation Agreement entered into between the company and Steamboat Capital, which beneficially owns above 5% of the comp

    3/20/26 8:30:00 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    Nu Skin Appoints Chayce Clark as COO

    Clark to expand on his responsibilities as chief legal officer to oversee company operational functions and revenue performance Nu Skin Enterprises Inc. (NYSE:NUS) today announced the appointment of Chayce Clark as chief operating officer effective immediately. Clark will be responsible for leading the company's revenue performance and end-to-end operational execution across the business in addition to maintaining his role as the company's chief legal officer. "Chayce has been a valuable part of our executive team and an important voice in our efforts to become the world's leading intelligent beauty and wellness leadership opportunity platform," said Ryan Napierski, president and CEO. "

    3/9/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $MED
    $NUS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Product Officer Hatchett Steven Keith bought $52,855 worth of shares (5,500 units at $9.61), increasing direct ownership by 3% to 167,565 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    11/12/25 4:32:45 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Chairman & CEO Chard Daniel R bought $5,003 worth of shares (381 units at $13.13) (SEC Form 4)

    4 - MEDIFAST INC (0000910329) (Issuer)

    6/17/25 6:20:00 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    Chief Product Officer Hatchett Steven Keith bought $49,010 worth of shares (6,500 units at $7.54), increasing direct ownership by 4% to 162,065 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    5/28/25 6:26:44 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $MED
    $NUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Medifast upgraded by DA Davidson with a new price target

    DA Davidson upgraded Medifast from Underperform to Neutral and set a new price target of $17.00 from $16.50 previously

    11/5/24 7:48:00 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    Medifast downgraded by DA Davidson with a new price target

    DA Davidson downgraded Medifast from Neutral to Underperform and set a new price target of $17.50 from $25.00 previously

    6/5/24 7:15:11 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    Stephens initiated coverage on Medifast with a new price target

    Stephens initiated coverage of Medifast with a rating of Equal-Weight and set a new price target of $82.00

    10/13/23 7:41:39 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    $MED
    $NUS
    Leadership Updates

    Live Leadership Updates

    View All

    Nu Skin Enterprises Appoints Chelsea Lantz as Interim Chief Financial Officer

    Nu Skin Enterprises, Inc. (NYSE:NUS) today announced the appointment of Chelsea Lantz as interim Chief Financial Officer, effective immediately. The appointment of Lantz comes after James Thomas stepped down as CFO to pursue an outside opportunity. "On behalf of our board, management and the entire Nu Skin team, we thank James for his leadership and significant contributions over 16 years at Nu Skin and wish him and his family well in their future pursuits," said Ryan Napierski, president and CEO. "We have a talented finance team who has led the ongoing work to improve our operational performance and strengthen our balance sheet over the past year. I am excited to work directly with Chels

    3/20/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Appoints Chayce Clark as COO

    Clark to expand on his responsibilities as chief legal officer to oversee company operational functions and revenue performance Nu Skin Enterprises Inc. (NYSE:NUS) today announced the appointment of Chayce Clark as chief operating officer effective immediately. Clark will be responsible for leading the company's revenue performance and end-to-end operational execution across the business in addition to maintaining his role as the company's chief legal officer. "Chayce has been a valuable part of our executive team and an important voice in our efforts to become the world's leading intelligent beauty and wellness leadership opportunity platform," said Ryan Napierski, president and CEO. "

    3/9/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Medifast Announces Planned Leadership Transition

     Nicholas Johnson Appointed President, and Expected to Succeed Dan Chard as CEO in June 2026; Chard to Remain Chairman Medifast, Inc. (NYSE:MED) today announced a planned leadership transition designed to provide continuity and stability as the company continues its evolution toward metabolic health. Medifast Chairman & Chief Executive Officer Dan Chard has informed the Board of Directors that he plans to step down as Chief Executive Officer in June 2026. Chard will continue to serve as Chairman of the Board following the transition. The Board has appointed Medifast's Chief Field Operations Officer Nicholas Johnson as President of Medifast, effective immediately. Johnson will work clo

    1/5/26 9:00:00 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    $MED
    $NUS
    Financials

    Live finance-specific insights

    View All

    Medifast Announces Fourth Quarter and Full Year 2025 Financial Results

    Medifast (NYSE:MED), the health and wellness company known for its science-backed, coach-guided lifestyle system, today reported results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Revenue of $75.1 million, with revenue per active earning coach of $4,664 Independent active earning coaches of 16,100 Net loss of $18.1 million, or $1.65 per diluted share ("EPS"), which includes the tax provision charge to establish a non-cash valuation allowance on the Company's deferred tax balance of $12.1 million (or $1.10 per diluted share) Cash, cash equivalents, and investment Securities of $167.3 million and no debt Full Year 2025 Revenue of $385

    2/17/26 4:05:00 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    Nu Skin Enterprises Reports Fourth Quarter and Full-year 2025 Results Within Guidance

    Company provides initial outlook for Q1 and fiscal year 2026, forecasting a return to revenue growth by year's end Nu Skin Enterprises Inc. (NYSE:NUS) today announced fourth quarter and full-year 2025 revenue and earnings within guidance with more than 50% growth in earnings for 2025. Executive Summary Q4 2025 vs. Prior-year Quarter Revenue $370.3 million; (16.9)% or (10.4)% excluding Mavely 2024 revenue (0.2)% FX impact or $(0.8) million Earnings Per Share (EPS) $0.29 compared to $(0.73) or $0.38 excluding restructuring and other charges Customers 748,796; (10)% Paid Affiliates 129,311; (11)% Sales Leaders 30,045; (

    2/12/26 4:06:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises Announces Quarterly Dividend

    Nu Skin Enterprises, Inc. (NYSE:NUS) today announced its board of directors has declared a quarterly cash dividend of $0.06 per share, which will be paid on Mar. 11, 2026, to shareholders of record on Feb. 27, 2026. About Nu Skin Enterprises Inc. Nu Skin Enterprises Inc. (NYSE:NUS) is an intelligent beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by more than 40 years of scientific research, the company's products help people look, feel and live their best with our newly introduced Prysm iO intelligent wellness platform, an award-winning line of beauty device systems and trusted brands in personal ca

    2/12/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $MED
    $NUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

    SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

    11/12/24 4:47:17 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

    SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

    11/6/24 10:20:59 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

    SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

    11/4/24 10:21:31 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care